A View LCS vs Imbio PHA (4.0.0)
AI Verdict
Choose A View LCS if…
Choose A View LCS if your primary need is a comprehensive AI-powered platform for multi-disease thoracic screening from a single low-dose CT scan. This tool is ideal for programs focused on early detection of lung cancer, quantification of emphysema, and assessment of coronary artery calcification, providing automated nodule analysis, Lung-RADS scoring, and detailed reports.
View A View LCS →Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA (4.0.0) if you require rapid, automated AI analysis of CT pulmonary angiogram (CTPA) scans to assess cardiac structures. This tool is specifically designed to aid in the diagnosis and risk stratification of pulmonary embolism and hypertension by providing automated measurements of ventricular and arterial diameters and calculating crucial ratios like RV/LV.
View Imbio PHA (4.0.0) →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | A View LCS | Imbio PHA (4.0.0) |
|---|---|---|
| Deployment | Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker). It can also be integrated into standard reading environments (PACS), RIS (Radiological Information System), or used as a standalone third-party application or web-based application. | Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Imbio PHA (4.0.0)Imbio PHA emphasizes seamless integration with native DICOM tools and workflows, delivering annotated images and summary reports directly into PACS without additional steps for the physician. Its focus on 'no user interfaces to learn' and 'results are ready when you are' suggests a highly streamlined and less disruptive user experience. A View LCS also offers automation and integration, but Imbio's explicit commitment to minimal user intervention gives it a slight edge.
Clinical Value
A View LCSA View LCS offers a comprehensive thoracic CT analysis, detecting lung nodules, quantifying emphysema, and assessing coronary artery calcification from a single low-dose CT scan. This '3-in-1 solution' provides a broader range of clinical insights and efficiency compared to Imbio PHA, which specializes in cardiac measurements for pulmonary embolism and hypertension from CTPA scans.
Pricing & Value
A View LCSBoth tools require direct contact for pricing, limiting transparency. However, A View LCS provides more detail on its pricing models, including one-off payments, subscriptions, and case-based scaling. Furthermore, it highlights significant ROI through '89% faster case throughput and 60% reduction in interpretation time,' offering a clearer value proposition despite the lack of specific cost figures.
Enterprise Readiness
A View LCSBoth tools are FDA-cleared, HIPAA compliant, and offer flexible deployment options. However, A View LCS explicitly mentions GDPR certification and recent FDA clearance renewal after meeting strengthened cybersecurity criteria. Its detailed 'security-first delivery' approach, including compliance and auditability, demonstrates a more robust and transparent commitment to enterprise-level security and compliance.
Innovation
A View LCSA View LCS demonstrates greater innovation with its '3-in-1 solution' that integrates multiple thoracic analyses into a 'single, continuous analytical pipeline' from a low-dose CT scan. The inclusion of 'CT kernel conversion AI technology' and a portfolio of 'over 20 cumulative US patents' further highlights its advanced technological development and innovative approach to comprehensive diagnostic imaging.
Support & Docs
Imbio PHA (4.0.0)Imbio PHA offers more explicit and comprehensive support details, including 24/7/365 global phone and email support, an online case submission form, and readily available user manuals for various product versions. While A View LCS provides contact information, Imbio's detailed commitment to continuous global support and accessible documentation is more robust.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | A View LCS | Imbio PHA (4.0.0) |
|---|---|---|
| Product Name | A View LCS | Imbio PHA (4.0.0) |
| Company | Coreline Soft Co. | Imbio |
| Tagline | AI-powered medical imaging for comprehensive thoracic disease diagnosis. | Transforming Imaging with AI to turn medical images into life-changing insights. |
| Core Analytical Scope | Comprehensive thoracic CT analysis, specializing in lung cancer screening, emphysema quantification, and coronary artery calcification detection from a single low-dose CT scan. | Automatically measures cardiac structures from CT pulmonary angiogram (CTPA) scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension. |
| Specific Measurement Capabilities | Automated lung nodule detection and classification, Nodule volume quantification and measurement (3D), Emphysema analysis and quantification (LAA), Coronary Artery Calcium (CAC) scoring (Agatston, volume, mass). | Automated measurement of right and left ventricle diameters, Automated measurement of main pulmonary artery and aorta diameters, Calculates RV/LV and PA/Ao ratios. |
| Output/Reporting Formats | Automated comprehensive report generation (PDF, DICOM PDF, SR) | Generates annotated DICOM images, Provides summary reports in PDF format |
Videos
Demos, reviews, and walkthroughs featuring A View LCS and Imbio PHA (4.0.0).